Liminatus Pharma Ord Shs Class A
LIMN0.864USD
+0.025+2.98%
Close 12/08, 16:00（ET）Quotes delayed by 15 min
--Market Cap
LossP/E TTM
More Details of Company
Liminatus Pharma Ord Shs Class A Info
Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -
Company Executives of Liminatus Pharma Ord Shs Class A
Name
Name/Position
Position
Shareholding
Change
Mr. Chris Kim
Mr. Chris Kim
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Rohit Nanani
Mr. Rohit Nanani
Director
Director
--
--
Dr. Eun Sook Lee, M.D., Ph.D.
Dr. Eun Sook Lee, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Sang-jin Daniel Lee
Mr. Sang-jin Daniel Lee
Head - Research & Development
Head - Research & Development
--
--
Mr. Richard Baek
Mr. Richard Baek
Director
Director
--
--
Dr. Byong C. Yoo, Ph.D.
Dr. Byong C. Yoo, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Mr. Beom K. Choi
Mr. Beom K. Choi
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Philip Lemons
Mr. Philip Lemons
Director
Director
--
--
Ms. Ji Yeon Baek
Ms. Ji Yeon Baek
Independent Director
Independent Director
--
--
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Chris Kim
Mr. Chris Kim
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Rohit Nanani
Mr. Rohit Nanani
Director
Director
--
--
Dr. Eun Sook Lee, M.D., Ph.D.
Dr. Eun Sook Lee, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Sang-jin Daniel Lee
Mr. Sang-jin Daniel Lee
Head - Research & Development
Head - Research & Development
--
--
Mr. Richard Baek
Mr. Richard Baek
Director
Director
--
--
Dr. Byong C. Yoo, Ph.D.
Dr. Byong C. Yoo, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Reporting Period
No. of institutions
Shares Held
Proportion
Change
No Data
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
No Data
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Liminatus Pharma Ord Shs Class A?
The top five shareholders of Liminatus Pharma Ord Shs Class A are:
What are the top three shareholder types of Liminatus Pharma Ord Shs Class A?
The top three shareholder types of Liminatus Pharma Ord Shs Class A are:
Other
Other
How many institutions hold shares of Liminatus Pharma Ord Shs Class A (LIMN)?
As of --, -- institutions hold shares of Liminatus Pharma Ord Shs Class A, with a combined market value of approximately --, accounting for --% of the total shares. Compared to --, institutional shareholding has increased by --.
What is the biggest source of revenue for Liminatus Pharma Ord Shs Class A?
In --, the -- business generated the highest revenue for Liminatus Pharma Ord Shs Class A, amounting to -- and accounting for --% of total revenue.
